SEC Comment Letter for GSK (GSK) — Jun 23, 2015
GSK plc
Date: June 23, 2015 · CIK: 0001131399 · Accession: 0000000000-15-032978
AI Filing Summary & Sentiment
Show Raw Text
June 23, 2015
Via E -mail
Mr. Simon Dingemans
Chief Financial Officer
GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Re: GlaxoSmithKline plc
Form 20-F for the Fiscal Year Ended December 31 , 2014
Filed February 27, 2015
File No. 1-15170
Dear Mr. Dingemans :
We have completed our review of your filing. We remind you that our comments or
changes to disclosu re in response to our comments do not foreclose the Commission from taking
any action with respect to the company or the filing and the compa ny may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities la ws of the United States . We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the
information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Sharon M. Blume
Sharon M. Blume
Accounting Branch Chief